HBX causes cyclin D1 overexpression and development of breast cancer in transgenic animals that are heterozygous for p53

被引:36
作者
Klein, A
Guhl, E
Tzeng, YJ
Fuhrhop, J
Levrero, M
Graessmann, M
Graessmann, A
机构
[1] Free Univ Berlin, Inst Mol Biol & Biochem, D-14195 Berlin, Germany
[2] Tzu Chi Univ, Grad Inst Mol & Cell Biol, Hualien 970, Taiwan
[3] Univ Roma La Sapienza, Fdn A Cesalpino, Gene Express Lab, I-00161 Rome, Italy
关键词
HBX; transgenic animals; ME-cell immortalization; cyclin D1; differentiation; tumor formation;
D O I
10.1038/sj.onc.1206539
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Transgenic mice, which selectively express the WAP-HBX transgene in mammary gland epithelial cells (ME-cells), were established in order to elucidate the consequences of HBX gene expression on organ differentiation, cell death program and tumor development. Transgene expression was demonstrable by RT-PCR, Northern and Western blot analysis during pregnancy, lactation and after weaning. HBX synthesis neither affect mammary gland differentiation nor apoptosis in ME-cells. Although breast cancer formation was rare in WAP-HBX animals (<1%), WAP-HBX.p53+/- hybrid animals developed breast tumors at an increased rate (12/85) after a latency period of 8-18 months. We also show here for the first time that HBX can immortalize ME-cells generated from mammary gland tissue segments in a p53-independent fashion. HBX causes cyclin D1 gene overexpression during early pregnancy, and this is maintained in ME-cells isolated either from mammary gland or from breast tumors. Intranuclear cyclin D1 accumulation also occurs in the absence of external growth factors and the BrdU incorporation rate remains high under serum starvation conditions. Finally, both cyclin D1 induction and HBX mitotic activity are dependent on p38 and c-Jun N-terminal kinase, but not on MEK-1 kinase activity.
引用
收藏
页码:2910 / 2919
页数:10
相关论文
共 47 条
  • [31] Pro-apoptotic effect of the hepatitis B virus X gene
    Pollicino, T
    Terradillos, O
    Lecoeur, H
    Gougeon, ML
    Buendia, MA
    [J]. BIOMEDICINE & PHARMACOTHERAPY, 1998, 52 (09) : 363 - 368
  • [32] Sambrook J., 2002, MOL CLONING LAB MANU
  • [33] Santarelli R, 1996, ONCOGENE, V12, P495
  • [34] Siegel PM, 2000, BIOESSAYS, V22, P554, DOI 10.1002/(SICI)1521-1878(200006)22:6<554::AID-BIES8>3.0.CO
  • [35] 2-A
  • [36] Hepatitis B virus X mutants, present in hepatocellular carcinoma tissue abrogate both the antiproliferative and transactivation effects of HBx
    Sirma, H
    Giannini, C
    Poussin, K
    Paterlini, P
    Kremsdorf, D
    Bréchot, C
    [J]. ONCOGENE, 1999, 18 (34) : 4848 - 4859
  • [37] Slagle BL, 1996, MOL CARCINOGEN, V15, P261, DOI 10.1002/(SICI)1098-2744(199604)15:4<261::AID-MC3>3.0.CO
  • [38] 2-J
  • [39] Role of NF-κB and Myc proteins in apoptosis induced by hepatitis B virus HBx protein
    Su, F
    Theodosis, CN
    Schneider, RJ
    [J]. JOURNAL OF VIROLOGY, 2001, 75 (01) : 215 - 225
  • [40] Hepatitis B virus HBx protein sensitizes cells to apoptotic killing by tumor necrosis factor alpha
    Su, F
    Schneider, RJ
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (16) : 8744 - 8749